Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Expenses:
Research and development	$ 987,239	$ 2,252,890	$ 2,930,302	$ 4,006,538
General and administrative	1,342,210	1,050,004	2,304,928	3,694,529
Total Operating Loss	(2,329,449)	(3,302,894)	(5,235,230)	(7,701,067)
Gain on settlement of lawsuit	825,000		825,000
Research and development tax credit	42,685		42,685
Investment income	5,556	8,075	11,725	16,750
Net Loss	(1,456,208)	(3,294,819)	(4,355,820)	(7,684,317)
Dividend paid-in kind to preferred shareholders		(50)		(14,057)
Net Loss Applicable to Common Shareholders	$ (1,456,208)	$ (3,294,869)	$ (4,355,820)	$ (7,698,374)
Basic and Diluted Loss Per Common Share	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	381,574,365	370,354,643	379,483,491	367,795,241